 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, today announced that its observational registry comparing the safety and effectiveness of INOmax nitric oxide gas, for inhalation, in term and near-term neonates to that in preterm neonates with pulmonary hypertension PH was ended early due to achievement of the pre-specified primary outcome measure, non-inferiority 95 percent confidence interval: -0.0021, 0.1158, with a pre-defined margin of -0.1452. The decision was made following the second planned interim analysis at 75 percent enrollment. The company intends to share the results of this study in an appropriate scientific forum soon. 